
mountsinai.org
Jul 4, 2025, 02:17
Joshua Richter: Linvoseltamab-gcpt Receives FDA Accelerated Approval for Multiple Myeloma
Joshua Richter, Associate Professor of Medicine, Hematology, and Medical Oncology at The Tisch Cancer Institute, shared on X:
“Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma | Regeneron Pharmaceuticals Inc. Read more.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 10, 2025, 20:21
Jul 10, 2025, 20:08
Jul 10, 2025, 16:59